ASP Isotopes (NASDAQ:ASPI) Given New $5.50 Price Target at HC Wainwright

ASP Isotopes (NASDAQ:ASPI) had its price target upped by HC Wainwright from $5.25 to $5.50 in a research note released on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for ASP Isotopes’ FY2024 earnings at ($0.11) EPS and FY2025 earnings at ($0.07) EPS.

ASP Isotopes Trading Up 0.3 %

ASP Isotopes stock opened at $3.10 on Wednesday. The stock has a 50-day moving average of $3.67 and a two-hundred day moving average of $2.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.85 and a current ratio of 1.85. ASP Isotopes has a one year low of $0.28 and a one year high of $4.97. The stock has a market cap of $151.65 million, a PE ratio of -6.33 and a beta of 5.03.

Insider Buying and Selling at ASP Isotopes

In other ASP Isotopes news, Director Robert John Andrew Ryan purchased 15,596 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was bought at an average cost of $2.35 per share, for a total transaction of $36,650.60. Following the completion of the purchase, the director now owns 537,055 shares in the company, valued at approximately $1,262,079.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 26.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of ASP Isotopes in the fourth quarter worth about $26,000. Millennium Management LLC purchased a new position in shares of ASP Isotopes in the fourth quarter worth about $49,000. HTLF Bank purchased a new position in shares of ASP Isotopes in the fourth quarter worth about $141,000. Citadel Advisors LLC purchased a new position in shares of ASP Isotopes in the fourth quarter worth about $187,000. Finally, Rathbones Group PLC purchased a new position in shares of ASP Isotopes in the fourth quarter worth about $272,000. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.